• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.".对“将本妥昔单抗与地塞米松、大剂量阿糖胞苷和顺铂联合用于复发或难治性霍奇金淋巴瘤的挽救治疗：II期HOVON/LLPC移植BRAVE研究”的评论。
Haematologica. 2021 Apr 1;106(4):1226-1227. doi: 10.3324/haematol.2020.278203.
2
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.本妥昔单抗联合地塞米松、大剂量阿糖胞苷和顺铂作为复发/难治性经典型霍奇金淋巴瘤挽救治疗的Ⅰ期剂量递增研究：HOVON/LLPC移植BRAVE研究
Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31.
3
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.在复发或难治性霍奇金淋巴瘤中，将 Brentuximab vedotin 与地塞米松、高剂量阿糖胞苷和顺铂联合作为挽救治疗：HOVON/LLPC 移植 BRaVE 研究的 II 期研究。
Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238.
4
Combining Brentuximab Vedotin With Dexamethasone, High-dose Cytarabine, and Cisplatin as Salvage Treatment in Pediatric Relapsed or Refractory Classic Hodgkin Lymphoma: Two Case Reports.Brentuximab Vedotin 联合地塞米松、高剂量阿糖胞苷和顺铂治疗儿科复发或难治性经典霍奇金淋巴瘤：两例报告。
J Pediatr Hematol Oncol. 2024 Aug 1;46(6):e439-e442. doi: 10.1097/MPH.0000000000002904. Epub 2024 Jun 24.
5
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.帕博利珠单抗单药治疗在接受挽救性自体干细胞移植和/或维布妥昔单抗治疗后复发的原发性难治性经典型霍奇金淋巴瘤患者中的应用：KEYNOTE-087亚组分析
Leuk Lymphoma. 2020 Apr;61(4):950-954. doi: 10.1080/10428194.2019.1702178. Epub 2020 Jan 6.
6
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.复发或难治性霍奇金淋巴瘤患者使用维布妥昔单抗的5年生存率和疗效持久性结果
Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.
7
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.与铂类方案相比，本妥昔单抗联合苯达莫司汀作为复发/难治性霍奇金淋巴瘤一线挽救治疗及自体造血干细胞移植“桥梁”的疗效对比
Leuk Lymphoma. 2023 Mar;64(3):742-745. doi: 10.1080/10428194.2022.2164195. Epub 2023 Jan 11.
8
Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.自体外周血干细胞移植后四周期 Brentuximab Vedotin 巩固治疗复发/难治性霍奇金淋巴瘤的安全性和有效性。
Leuk Lymphoma. 2020 Jul;61(7):1732-1735. doi: 10.1080/10428194.2020.1728755. Epub 2020 Feb 22.
9
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤自体移植前，以本妥昔单抗作为二线治疗的多中心II期试验结果。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.
10
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.在接受过大量治疗的复发或难治性霍奇金淋巴瘤患者中，接受本妥昔单抗和苯达莫司汀联合治疗的部分缓解者有较长的无进展生存期：一项国际多中心I/II期试验的更新结果
Leuk Lymphoma. 2020 Dec;61(12):3014-3017. doi: 10.1080/10428194.2020.1795161. Epub 2020 Jul 28.

引用本文的文献

1
Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study.对于年龄≤60岁的经典型霍奇金淋巴瘤患者，在接受两个周期的阿霉素-博来霉素-长春花碱-达卡巴嗪治疗后未获得完全代谢缓解时，苯达莫司汀强化联合 Brentuximab vedotin 作为早期挽救治疗：一项回顾性多中心研究的长期疗效结果。
Br J Haematol. 2025 May;206(5):1502-1507. doi: 10.1111/bjh.20053. Epub 2025 Apr 2.

本文引用的文献

1
Hodgkin lymphoma: outsmarting HRS cells.霍奇金淋巴瘤：智胜霍奇金和里德-斯腾伯格细胞。
Blood. 2020 Nov 19;136(21):2362-2364. doi: 10.1182/blood.2020008250.
2
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.在复发或难治性霍奇金淋巴瘤中，将 Brentuximab vedotin 与地塞米松、高剂量阿糖胞苷和顺铂联合作为挽救治疗：HOVON/LLPC 移植 BRaVE 研究的 II 期研究。
Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238.
3
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.吉西他滨和苯达莫司汀是复发性/难治性霍奇金淋巴瘤患者安全有效的挽救方案：一项 1/2 期研究的结果。
Cancer. 2020 Mar 15;126(6):1235-1242. doi: 10.1002/cncr.32640. Epub 2019 Dec 10.
4
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.Brentuximab vedotin 序贯泊马度胺超剂量治疗难治或复发霍奇金淋巴瘤。
Blood Adv. 2019 May 14;3(9):1546-1552. doi: 10.1182/bloodadvances.2019000123.
5
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).本妥昔单抗维布妥昔单抗和ESHAP 作为二线治疗霍奇金淋巴瘤患者非常有效（西班牙 GELTAMO 组试验的长期结果）。
Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009.
6
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.本妥昔单抗维迪西妥单抗联合苯达莫司汀：复发或难治性霍奇金淋巴瘤的高效一线挽救治疗方案。
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.
7
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.PET 适应序贯挽救治疗，采用 Brentuximab Vedotin 继以增强异环磷酰胺、卡铂和依托泊苷，用于复发和难治性霍奇金淋巴瘤患者：一项非随机、开放标签、单中心、2 期研究。
Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13.
8
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.本妥昔单抗维迪昔（SGN-35）治疗复发性 CD30 阳性淋巴瘤。
N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.

Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.".

作者信息

Picardi Marco, Giordano Claudia

机构信息

Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples.

出版信息

Haematologica. 2021 Apr 1;106(4):1226-1227. doi: 10.3324/haematol.2020.278203.

DOI:10.3324/haematol.2020.278203
PMID:33792226
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8018111/
Abstract
摘要